The Lancet最新文献

{"title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","authors":"Jia Xu, Lin Liu, Philippe Parone, Wei Xie, Chunyan Sun, Zhaozhao Chen, Jishuai Zhang, Chunrui Li, Yu Hu, Heng Mei","doi":"10.1016/s0140-6736(25)01030-x","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01030-x","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gavi replenishment falls short of US$9 billion target","authors":"Ann Danaiya Usher","doi":"10.1016/s0140-6736(25)01380-7","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01380-7","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"15 1","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mpox in DR Congo: a call to action","authors":"Fabrizio Maggi, Daniele Focosi","doi":"10.1016/s0140-6736(25)00673-7","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00673-7","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"20 1","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report – Authors' reply","authors":"David A Watkins, Angela Y Chang, Omar Karlsson, Wenhui Mao, Ole F Norheim, Osondu Ogbuoji, Marco Schäferhoff, Gavin Yamey, Dean Jamison","doi":"10.1016/s0140-6736(25)01093-1","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01093-1","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"74 1","pages":"31-32"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering women during childbirth","authors":"","doi":"10.1016/s0140-6736(25)01382-0","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01382-0","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"29 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report","authors":"Johanna Ralston, Simón Barquera, Louise Baur, Bruno Halpern, Jason C G Halford, Stephen Ogweno","doi":"10.1016/s0140-6736(25)01090-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01090-6","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"46 1","pages":"29-30"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report","authors":"Jeffrey V Lazarus, Meena B Bansal, Fasiha Kanwal, Holly Lofton, Kenneth Cusi","doi":"10.1016/s0140-6736(25)01091-8","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)01091-8","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"9 1","pages":"30-31"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study","authors":"Timothy B Hallett, Nicolas A Menzies, Stephen Resch, Carel Pretorius, John Stover, Jiaying Stephanie Su, Peter Winskill, Matt Gordon, Richard Grahn, Firdaus Mahmood, Mikaela Smit, Mehran Hosseini, Johannes Hunger","doi":"10.1016/s0140-6736(25)00831-1","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00831-1","url":null,"abstract":"<h3>Background</h3>The Sustainable Development Goals (SDGs) include ending the epidemics of HIV, tuberculosis, and malaria by 2030. With 5 years remaining to meet this goal, and with the Global Fund to Fight AIDS, Tuberculosis and Malaria seeking funding for programmes in 2027–29, establishing what can be achieved through continued investment in combatting these diseases is crucial. We aimed to estimate the potential for impact by analysing the funding landscape and epidemiological situations of these three diseases, the costs of key programmes, and the extent of possible future progress in the countries eligible for Global Fund support.<h3>Method</h3>In this modelling study, we developed estimates of the financial resources needed in Global Fund-supported countries to combat HIV, tuberculosis, and malaria from the global plans produced by UNAIDS, the Stop TB Partnership, and WHO. Estimates of available resources in the coming years were obtained by assuming that national expenditure on the three diseases would grow in line with general governmental expenditures, that the Global Fund would contribute an additional $18·0 billion, and that other developmental assistance would be at the same level in real terms as the average in the period 2020–22. Epidemiological and costing models for each of the three diseases were used to quantify the possible impact in Global Fund-eligible countries (including on aggregated mortality and incidence rates). The return on investment (ROI) was computed considering both the intrinsic value of health and the direct economic benefits of the reduced risk of morbidity and premature mortality. The analysis was completed at the end of 2024 with the latest available data, which pertained to the year 2023. The focus of the projection period was 2027–29, a period for which scale-up plans and funding have not yet been committed and the period when most of the resources raised by the eighth replenishment of the Global Fund would be used.<h3>Findings</h3>The total resource needs for the three diseases were estimated to be US$140·6 billion in 2027–29. We calculated that $111·3 billion (79%) of this need could be met from domestic financing ($69·7 billion), the Global Fund ($18·0 billion), and other external donors ($23·6 billion). Optimal use of these available resources could save 23 million lives and avert 400 million cases and new infections during 2027–29. The trajectory of the combined mortality rate for all diseases was projected to approach that needed to reach the SDG for 2030 (with a difference between the target in 2030 and the projection at the end of 2029 of between 1·5% and 15·5% of the normalised aggregated mortality rate), inequality in life expectancy between countries would be 7% lower by 2029, and 189 million fewer hospital days and 572 million fewer outpatient visits would be needed in 2027–29, saving $1·1 billion. For every $1·00 invested, there could be up to $19·00 in intrinsic health value created or $3·50","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiotherapy for nAMD: areas for improvement – Authors' reply","authors":"Timothy L Jackson, Helen Dakin, Xuemin Zhu, Hatem Wafa, Yanzhong Wang, Sarah Wordsworth, Barnaby C Reeves, Riti Desai, Lisa Ramazzotto, Chan Ning Lee","doi":"10.1016/s0140-6736(25)00664-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00664-6","url":null,"abstract":"No Abstract","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"29 1","pages":"26-27"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study","authors":"Tony Wawina-Bokalanga, Sydney Merritt, Eddy Kinganda-Lusamaki, Daan Jansen, Megan Halbrook, Áine O'Toole, Elisabeth Pukuta-Simbu, Emmanuel Hasivirwe Vakaniaki, Rilia Ola-Mpumbe, Papy Kwete-Mbokama, Prince Akil-Bandali, Cris Kacita, Ange Ponga-Museme, Nelson Mapenzi-Kashali, Adrienne Amuri-Aziza, Olivier Tshiani-Mbaya, Princesse Paku-Tshambu, Pedro H L F Dantas, Tessa De Block, Emmanuel Lokilo-Lofiko, Placide Mbala-Kingebeni","doi":"10.1016/s0140-6736(25)00294-6","DOIUrl":"https://doi.org/10.1016/s0140-6736(25)00294-6","url":null,"abstract":"<h3>Background</h3>Clade I monkeypox virus is endemic in DR Congo. We aim to describe the epidemiological trends of the cocirculating subclades Ia and Ib mpox outbreaks in Kinshasa, DR Congo.<h3>Methods</h3>This retrospective observational study included suspected and laboratory-confirmed mpox cases reported between Jan 1, 2023, and Oct 31, 2024, in Kinshasa. Skin lesion swabs or blood samples were collected as part of a routine countrywide mpox surveillance programme. To confirm the diagnosis of mpox, all samples were tested at the Institut National de Recherche Biomédicale (INRB) using real-time PCR. Whole-genome sequencing was conducted for phylogenomic analysis and assessment of <em>APOBEC3</em> type mutations. Samples that remained unassigned to subclade Ia or Ib after whole-genome sequencing and real-time PCR were labelled as an unknown subclade.<h3>Findings</h3>As part of routine disease surveillance, 1479 suspected mpox cases were reported in Kinshasa. Samples were collected from 1314 suspected mpox cases and tested by PCR at the INRB. 440 (34%) of 1314 suspected cases had PCR confirmed mpox, with the first confirmed mpox case detected on Aug 18, 2023. 262 (60%) of 440 cases were male, 172 (39%) were female, and six (1%) were unknown, and the median age was 26 years (IQR 19–34). The epidemiological curve suggests two distinct periods during the 2023–24 outbreaks in Kinshasa. Between Aug 18, 2023, and June 30, 2024 (period 1), 218 suspected mpox cases underwent investigation and 24 (11%) were PCR confirmed as mpox; all cases were identified as subclade Ia. After a decline in suspected and confirmed cases in early 2024, the first confirmed subclade Ib mpox case in Kinshasa was reported on July 1, 2024. Between July 1 and Oct 31, 2024 (period 2), 1096 suspected mpox cases were reported and 416 (38%) were PCR confirmed as mpox. In-depth epidemiological case investigations during period 1 identified three small, self-limiting transmission chains between August and September, 2023. Case investigation data were available for 127 cases with PCR confirmed mpox, including clinical symptom data available for 61 (64%) of 95 with subclade Ia. The most commonly reported symptoms were fever (49 [80%] of 61) and skin rash (48 [79%]). The most common lesion locations were genital or anorectal (35 [64%] of 55 cases with available data). Case investigation data were available for 32 cases with subclade Ib mpox, including clinical symptom data available for 21 (66%) with subclade Ib. The most commonly reported symptoms were skin rash (18 [86%] of 21) and fever (12 [57%]). Genital or anorectal involvement was reported in 13 (68%) of 19 cases with available lesion location data. Genomic analysis shows five separate self-limiting clusters of subclade Ia (group II sampled from August, 2023, to August, 2024) and two larger clusters (occurring from July, 2024, to October, 2024, in period 2) belonging to subclade Ia (group II) and subclade Ib. 32 (68%) of 47 mutati","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"79 1","pages":"63-75"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}